The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / FDA Approves Amgen’s Infliximab Biosimilar Treatment

FDA Approves Amgen’s Infliximab Biosimilar Treatment

December 10, 2019 • By Reuters Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters)—The U.S. Food and Drug Administration on Friday approved Amgen Inc.’s biosimilar copy of Johnson & Johnson’s blockbuster rheumatoid arthritis drug, Remicade (infliximab), according to the regulator’s website.

You Might Also Like
  • FDA Approves Biosimilar to J&J’s Remicade for Multiple Diseases
  • Pfizer’s Second Biosimilar of J&J’s Remicade Wins U.S. FDA Approval
  • Infliximab Biosimilar Receives FDA Approval

The biosimilar, Avsola (infliximab-axxq), has the same chemical components, dosage form and strength as Remicade and would treat a range of autoimmune disorders.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The label for the treatment carries a boxed warning, FDA’s harshest, flagging risks of serious infections and malignancy, similar to that of Remicade’s.

With the regulatory approval, Avsola joins the existing biosimilars to J&J’s drug, including Pfizer Inc’s 2017 approved Ixifi (infliximab-qbtx), Celltrion Inc’s Inflectra (infliximab-dyyb) and Merck & Co and Samsung Bioepis Co Ltd’s Renflexis (infliximab-abda).

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Avsola will add to Amgen’s growing biosimilar unit, which could be $2 billion over the next several years, says Jefferies analyst Michael Yee.

However, Mr. Yee doesn’t see the drug as a major driver of sales for Amgen right now.

Avsola was approved for all eligible indications of Remicade, including the treatment of bowel disease, Crohn’s disease and skin disorder plaque psoriasis, the agency said.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Biosimilars are medicines considered highly similar to an original drug and are cheaper alternatives to biologic products.

The blockbuster drug Remicade, approved in the U.S., E.U. and other regions, has steadily lost market share among patients enrolled in the Canadian province of Quebec’s public drug program and elsewhere, where biosimilars have been slowly catching on with doctors and patients.

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: Avsola, infliximab, infliximab biosimilar, infliximab-axxq, Remicade, REMICADE (infliximab), U.S. Food and Drug Administration (FDA)

You Might Also Like:
  • FDA Approves Biosimilar to J&J’s Remicade for Multiple Diseases
  • Pfizer’s Second Biosimilar of J&J’s Remicade Wins U.S. FDA Approval
  • Infliximab Biosimilar Receives FDA Approval
  • FDA Approves Adalimumab-atto, a Biosimilar of Humira

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)